|Bid||62.67 x 800|
|Ask||62.79 x 1000|
|Day's Range||62.27 - 64.70|
|52 Week Range||43.27 - 86.58|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||22.14|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.53|
Biogen Inc. (BIIB) today announced updates to the SPINRAZA (nusinersen) clinical development program including the initiation of a new global clinical trial, DEVOTE. The DEVOTE study will evaluate if a higher dose of SPINRAZA can provide even greater efficacy in the treatment of spinal muscular atrophy (SMA) across a broad patient population.
MELBOURNE, Australia, Sept. 17, 2019 /PRNewswire/ -- Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) therapy, is indicative of a positive drug effect of ATL1102 at the dose tested both at an immunomodulatory (i.e.
BOSTON and CARLSBAD, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), presented data today from the Phase 1 clinical trial of AKCEA-TTR-LRx in a poster presentation at the Heart Failure Society of America 23rd Annual Scientific Meeting in Philadelphia, Pennsylvania. AKCEA-TTR-LRx is an antisense drug developed using Ionis’ proprietary LIgand Conjugated Antisense (LICA) technology platform.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that data from the NEURO-TTR open-label study along with data from the AKCEA-TTR-LRx program and additional clinical presentations on the efficacy and safety profile of TEGSEDI will be presented at the 2nd European ATTR Amyloidosis Alliance Meeting in Berlin, Germany, September 2-3, 2019.
Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.
Details on presentation times or changes to presentation dates can be found on the Company's website. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.
CARLSBAD, Calif., Aug. 27, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that GSK exercised its option to license Ionis' antisense medicines for people with chronic hepatitis B virus (CHB) infection following positive Phase 2 results. Current treatments for patients with CHB provide low levels of hepatitis B virus S antigen seroclearance, leaving many patients without a treatment to achieve sustained disease remission. "By targeting the root cause of CHB-related liver disease, our antisense technology can potentially deliver a transformative medicine for people who suffer from chronic hepatitis B virus infection," said Brett P. Monia, chief operating officer at Ionis.
Chairman and CEO of Ionis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stanley T Crooke (insider trades) sold 22,000 shares of IONS on 08/21/2019 at an average price of $71.52 a share. Continue reading...
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the final study results from the Phase 3 APPROACH study evaluating WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome (FCS) were published in the August 8th issue of The New England Journal of Medicine (NEJM). It is caused by impaired production or function of the enzyme, lipoprotein lipase (LPL), responsible for breaking down chylomicrons, lipoproteins rich in triglycerides. WAYLIVRA is designed to reduce the production of apolipoprotein C-III (apoC-III), a protein produced in the liver that plays a central role in the regulation of plasma triglycerides.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 96.30% and 16.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) Allakos Inc (NASDAQ: ALLK )(announced common stock offering) ...
Q2 2019 year-to-date revenues increased more than 75% to $461 million SPINRAZA sales surpass $1 billion in the first half of 2019 Ionis on track for third consecutive year of net income Conference call ...
Achieved Second Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $10 Million Conference Call Webcast Tuesday, August 6, 4:30 p.m. ET at www.akceatx.com BOSTON,.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today topline results from the BROADEN study in patients with familial partial lipodystrophy (FPL). The study met its primary endpoint demonstrating a statistically significant reduction in triglyceride levels in patients with FPL treated with WAYLIVRA compared to placebo-treated patients. In addition to achieving the primary endpoint, the study achieved an important secondary endpoint of a statistically significant reduction in liver fat.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARLSBAD, Calif., July 30, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Wednesday, August 7th at 11:30 a.m. Eastern Time to discuss its second quarter 2019 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.